LE MOLTEPLICI PRECARIETÀ. NOTE IN MARGINE AD UN DIBATTITO

Il 2008 si chiude con vecchie preoccupazioni e nuovi allarmi su quell'universo di situazioni che siamo abituati a definire "lavoro precario"; ma il lavoro che manca e il lavoro che cambia costituiscono un nesso che investe l'organizzazione della società nel suo complesso

Topical butyrate for acute radiation proctisis: randomised, crossover trial

ISI:00008972490001

Efficacy and mucosal toxicity of concomitant chemo-radiotherapy in patients with locally-advanced squamous cell carcinoma of the head-and-neck in the light of a novel mathematical model

Background: In the last several decades, combined radiotherapy (RT) and chemotherapy (CT) have beenrecognized as feasible in locally-advanced-squamous-cell-carcinoma of the head-and-neck (LA-HNSCC).Several meta-analyses identified concurrent RT + CT (CRT) most likely effective approach respect toRT-alone. However, radiobiological models comparing different chemotherapeutic schedules againstdelivered RT fractionation schedule for overall survival and toxicity are still needed.Methods and materials: Based on 9 randomized trials (2785 patients), radiobiological models andmultivariate logistic regression model were used to derive dose-response curves and estimate the 5-year-overall survival (OS) and ≥G3 acute mucositis rate of CRT or RT-alone.Results: Equivalent dose at 2 Gy/fraction (EQD2) was calculated using the linear quadratic model. Theeffect of CRT schedules, considering the CT type and its administration schedule and the HPV status oftumors were estimated using the univariate/multivariate logistic regression. The multivariate logisticregression model for 5y-OS indicated EQD2 and the type of CT, the chemo-sensitization fraction and theHPV status significant prognostic factors, while for toxicity both EQD2 and the concomitant adminis-tration of 5-fluorouracil (5Fu) resulted as significant prognostic factors. Combined schedules cisplatin(DDP)+/−5Fu + RT produced the higher OS compared with combined carboplatin+/−5Fu + RT or RT-alone

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

none80noBackground: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement of anti-HER2 treatments, we performed a large, multicenter, retrospective study of HER2-positive BC patients. Methods: The observational PANHER study included 1,328 HER2-positive advanced BC patients treated with HER2 blocking agents since June 2000 throughout July 2020. Endpoints of efficacy were progression-free survival (PFS) and overall survival (OS). Results: Patients who received a first-line pertuzumab-based regimen showed better PFS (p < 0.0001) and OS (p = 0.004) than those receiving other treatments. Median PFS and mOS from second-line starting were 8 and 28 months, without significant differences among various regimens. Pertuzumab-pretreated patients showed a mPFS and a mOS from second-line starting not significantly affected by type of second line, that is, T-DM1 or lapatinib/capecitabine (p = 0.80 and p = 0.45, respectively). Conversely, pertuzumab-naïve patients receiving second-line T-DM1 showed a significantly higher mPFS compared with that of patients treated with lapatinib/capecitabine (p = 0.004). Median OS from metastatic disease diagnosis was higher in patients treated with trastuzumab-based first line followed by second-line T-DM1 in comparison to pertuzumab-based first-line and second-line T-DM1 (p = 0.003), although these data might be partially influenced by more favorable prognostic characteristics of patients in the pre-pertuzumab era. No significant differences emerged when comparing patients treated with ‘old’ or ‘new’ drugs (p = 0.43), even though differences in the length of the follow-up between the two cohorts should be taken into account. Conclusion: Our results confirmed a relevant impact of first-line pertuzumab-based treatment and showed lower efficacy of second-line T-DM1 in trastuzumab/pertuzumab pretreated, as compared with pertuzumab-naïve patients. Our findings may help delineate a more appropriate therapeutic strategy in HER2-positive metastatic BC. Prospective randomized trials addressing this topic are awaited.restrictedPizzuti L.; Krasniqi E.; Sperduti I.; Barba M.; Gamucci T.; Mauri M.; Veltri E.M.; Meattini I.; Berardi R.; Di Lisa F.S.; Natoli C.; Pistelli M.; Iezzi L.; Risi E.; D'Ostilio N.; Tomao S.; Ficorella C.; Cannita K.; Riccardi F.; Cassano A.; Bria E.; Fabbri M.A.; Mazzotta M.; Barchiesi G.; Botticelli A.; D'Auria G.; Ceribelli A.; Michelotti A.; Russo A.; Salimbeni B.T.; Sarobba G.; Giotta F.; Paris I.; Saltarelli R.; Marinelli D.; Corsi D.; Capomolla E.M.; Sini V.; Moscetti L.; Mentuccia L.; Tonini G.; Raffaele M.; Marchetti L.; Minelli M.; Ruggeri E.M.; Scavina P.; Bacciu O.; Salesi N.; Livi L.; Tinari N.; Grassadonia A.; Fedele Scinto A.; Rossi R.; Valerio M.R.; Landucci E.; Stani S.; Fratini B.; Maugeri-Sacca M.; De Tursi M.; Maione A.; Santini D.; Orlandi A.; Lorusso V.; Cortesi E.; Sanguineti G.; Pinnaro P.; Cappuzzo F.; Landi L.; Botti C.; Tomao F.; Cappelli S.; Bon G.; Pelle F.; Cavicchi F.; Fiorio E.; Foglietta J.; Scagnoli S.; Marchetti P.; Ciliberto G.; Vici P.Pizzuti, L.; Krasniqi, E.; Sperduti, I.; Barba, M.; Gamucci, T.; Mauri, M.; Veltri, E. M.; Meattini, I.; Berardi, R.; Di Lisa, F. S.; Natoli, C.; Pistelli, M.; Iezzi, L.; Risi, E.; D'Ostilio, N.; Tomao, S.; Ficorella, C.; Cannita, K.; Riccardi, F.; Cassano, A.; Bria, E.; Fabbri, M. A.; Mazzotta, M.; Barchiesi, G.; Botticelli, A.; D'Auria, G.; Ceribelli, A.; Michelotti, A.; Russo, A.; Salimbeni, B. T.; Sarobba, G.; Giotta, F.; Paris, I.; Saltarelli, R.; Marinelli, D.; Corsi, D.; Capomolla, E. M.; Sini, V.; Moscetti, L.; Mentuccia, L.; Tonini, G.; Raffaele, M.; Marchetti, L.; Minelli, M.; Ruggeri, E. M.; Scavina, P.; Bacciu, O.; Salesi, N.; Livi, L.; Tinari, N.; Grassadonia, A.; Fedele Scinto, A.; Rossi, R.; Valerio, M. R.; Landucci, E.; Stani, S.; Fratini, B.; Maugeri-Sacca, M.; De Tursi, M.; Maione, A.; Santini, D.; Orlandi, A.; Lorusso, V.; Cortesi, E.; Sanguineti, G.; Pinnaro, P.; Cappuzzo, F.; Landi, L.; Botti, C.; Tomao, F.; Cappelli, S.; Bon, G.; Pelle, F.; Cavicchi, F.; Fiorio, E.; Foglietta, J.; Scagnoli, S.; Marchetti, P.; Ciliberto, G.; Vici, P